BioRestorative Therapies Business Summary

BioRestorative Therapies, Inc. (BRTX) is a late-stage clinical biotechnology company that generates revenue through its commercial BioCosmeceutical platform and the pursuit of strategic licensing and co-development partnerships. The business is primarily organized into two clinical segments: the Disc/Spine Program, which features the lead autologous cell therapy candidate BRTX-100 for chronic lumbar disc disease, and the Metabolic Program, focused on the ThermoStem platform for treating obesity and diabetes using brown adipose-derived stem cells. As of February 2026, the company has successfully completed Phase 2 enrollment for BRTX-100 and is preparing for a Phase 3 IND submission following favorable FDA Type B meeting outcomes. Within the regenerative medicine market, BioRestorative competes with firms such as Mesoblast, DiscGenics, and Regeneron Pharmaceuticals, distinguishing itself through proprietary hypoxic culturing technology designed for low-oxygen, avascular environments. Originally incorporated in 1997, the company is currently led by Chairman and CEO Lance Alstodt, a former investment banker with a 25-year pedigree in healthcare M&A at institutions including J.P. Morgan and Bank of America Merrill Lynch. The technical and scientific core is managed by Francisco Silva, Vice President of Research and Development and Chief Scientist, a veteran researcher specializing in stem cell protocols and tissue engineering. The leadership team also includes CFO Robert Kristal and Head of Global Commercial Operations Crystal Romano, the latter of whom joined in late 2025 to scale the company's commercial footprint. Notable institutional investors and board members include Westbury Bermuda Ltd, the company’s largest shareholder, alongside Dr. Nickolay Kukekov and David Rosa, providing a blend of clinical and capital markets expertise.